IntraBio Inc: Clinical Trials

7 trials sponsored by IntraBio Inc, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 recruiting, 1 active not recruiting, 1 approved for marketing. 3 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Terminated 1
Phase 33Recruiting 2, Active not recruiting 1

Follow IntraBio Inc: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pivotal Study of N-acetyl-L-leucine for CACNA1A
N-Acetyl-L-Leucine, Placebo - CACNA1A, Spinocerebellar Ataxia Type 6
Phase 3RecruitingIntraBio Inc602026-08-172026-09-08
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
N-Acetyl-L-Leucine, Placebo - Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
Phase 3Active not recruitingIntraBio Inc602025-03-182025-07-03
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
N-Acetyl-L-Leucine, Placebo - Niemann-Pick Disease, Type C
Phase 3RecruitingIntraBio Inc532022-06-302026-04-03
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
IB1001 - Ataxia Telangiectasia
Phase 2TerminatedIntraBio Inc172020-01-082026-03-25
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
IB1001 - Niemann-Pick Disease, Type C
Phase 2CompletedIntraBio Inc332019-09-042023-11-28
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
IB1001 - GM2 Gangliosidosis, Tay-Sachs Disease
Phase 2CompletedIntraBio Inc302019-06-072024-03-12
Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T)
Levacetylleucine - Ataxia-Telangiectasia (A-T)
Approved for marketingIntraBio Inc2026-09-28

Conditions studied

Ataxia Telangiectasia (3)  ·  Niemann-Pick Disease, Type C (2)  ·  Episodic Ataxia, Type 2 (1)  ·  Gangliosidoses, GM2 (1)  ·  Sandhoff Disease (1)  ·  Spinocerebellar Ataxias (1)  ·  Tay-Sachs Disease (1)

Interventions

acetylleucine (7)  ·  IB1001 (5)

Countries

Germany (6)  ·  United Kingdom (6)  ·  United States (6)  ·  Spain (4)  ·  Slovakia (3)  ·  Switzerland (3)  ·  Australia (1)  ·  Austria (1)  ·  Czechia (1)  ·  Greece (1)  ·  Italy (1)  ·  Netherlands (1)

Results publications

PMID 33482890, PMID 34349180, PMID 34387740, PMID 40739200, PMID 30115089, PMID 33738443, PMID 34620022, PMID 36456200, PMID 38294974, PMID 40513057, PMID 42309084, PMID 42467089

NIH funding

2025 (1)